| __timestamp | Johnson & Johnson | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 22746000000 | 60987000 |
| Thursday, January 1, 2015 | 21536000000 | 125542000 |
| Friday, January 1, 2016 | 21685000000 | 210460000 |
| Sunday, January 1, 2017 | 25354000000 | 275119000 |
| Monday, January 1, 2018 | 27091000000 | 409539000 |
| Tuesday, January 1, 2019 | 27556000000 | 547758000 |
| Wednesday, January 1, 2020 | 28427000000 | 736300000 |
| Friday, January 1, 2021 | 23402000000 | 904200000 |
| Saturday, January 1, 2022 | 24596000000 | 1080300000 |
| Sunday, January 1, 2023 | 26553000000 | 1262200000 |
| Monday, January 1, 2024 | 27471000000 | 1530500000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, understanding the cost of revenue is crucial for evaluating a company's financial health. This analysis focuses on two giants: Johnson & Johnson and Vertex Pharmaceuticals Incorporated, from 2014 to 2023.
Johnson & Johnson, a stalwart in the healthcare sector, has seen its cost of revenue grow by approximately 17% over the past decade. Starting at around $22.7 billion in 2014, it peaked at $28.4 billion in 2020, reflecting its expansive operations and consistent market presence.
In contrast, Vertex Pharmaceuticals, known for its innovative treatments, has experienced a staggering 1,970% increase in its cost of revenue, from a modest $61 million in 2014 to $1.26 billion in 2023. This growth underscores Vertex's aggressive expansion and investment in cutting-edge research.
Cost of Revenue Comparison: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Johnson & Johnson vs Vertex Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Johnson & Johnson vs Viatris Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Cost of Revenue: Key Insights for Johnson & Johnson and MorphoSys AG
Johnson & Johnson vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and Pharming Group N.V.
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs MorphoSys AG
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Vericel Corporation
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated